$MRNS News
Last published 1y ago
- 1y agoMRNSApproval of Ztalmy, Nda #215904 (Labeling)FDA Approved DrugsApproval Date: 10/16/2025; Drug Name: Ztalmy, Nda #215904; Active Ingredients: GANAXOLONE; Company: Marinus; Submission Status: Approval; Submission Classification: Labeling; Application Number: 215904
- 1y agoMRNSApproval of Ztalmy, Nda #215904 (Efficacy)FDA Approved DrugsApproval Date: 10/16/2025; Drug Name: Ztalmy, Nda #215904; Active Ingredients: GANAXOLONE; Company: Marinus; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 215904
- 1y agoLBRDAMRNSOMICVCSAKuehn Law Encourages MRNS, OMIC, LBRDA, and VCSA Investors to Contact Law FirmGlobeNewswireNEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 1y agoMRNSImmedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.Business WireImmedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, today
- 1y agoMRNSMarinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial ResultsBusiness WireZTALMY® (ganaxolone) Q3 2024 net product revenue of $8.5 million representing growth of 56% versus Q3 2023 Narrowing full year 2024 ZTALMY net product revenue guidance to $33 to $34 million Reported results
- 2y agoMRNSMarinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic AlternativesBusiness WireTrial did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency (p=0.09); results showed numerically higher response rates for ganaxolone than placebo Ganaxolone was generally
- 2y agoMRNSMarinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual MeetingBusiness WireMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today presented new data from the pivotal Phase 3 RAISE trial
- 2y agoMRNSMarinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration RegimensBusiness WireNew U.S. patent issued for ZTALMY® (ganaxolone) oral titration regimens cover the treatment of a range of epilepsy disorders, expiring September 2042 Marinus continues to grow its IP portfolio to protect its
- 2y agoMRNSMarinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual MeetingBusiness WireIncludes additional data from the Phase 3 RAISE trial in refractory status epilepticus (SE) and data from a retrospective claims-based analysis on the management of SE Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a
- 2y agoMRNSMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to one new
- 2y agoMRNSMarinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst DayBusiness WireEnrollment complete and on track to report topline data from the TrustTSC trial in tuberous sclerosis complex (TSC) in the first half of Q4 with NDA filing targeted for April 2025 TrustTSC maintained a double-blind
- 2y agoMRNSMarinus Pharmaceuticals, Inc. vs Ovid Therapeutics Inc. - AIA Trial, Institution DeniedUS Patent Trial and Appeal Board
- 2y agoMRNSMarinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024Business WireMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced agenda topics and speakers for its upcoming
- 2y agoMRNSMarinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare ConferenceBusiness WireMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will participate in a fireside
- 2y agoMRNSMarinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024Business WireMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will host an Investor and Analyst Day on Friday, September 20
- 2y agoMRNSMarinus Pharmaceuticals, Inc. (MRNS) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoMRNSMarinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial ResultsBusiness WireZTALMY® (ganaxolone) Q2 2024 net product revenue of $8.0 million representing strong growth of 87% versus Q2 2023 On track to achieve full year 2024 ZTALMY net product revenue guidance of between $33 and $35
- 2y agoAGENAMGNCASILGND+8Ligand Reports Second Quarter 2024 Financial ResultsBusiness WireConference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast
- 2y agoMRNSOvid Therapeutics, Inc. vs Marinus Pharmaceuticals, Inc. - AIA Trial, Final Written DecisionUS Patent Trial and Appeal Board
- 2y agoMRNSMarinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024Business WireMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for
- 2y agoMRNSDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MarinusPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Marinus Pharmaceuticals, Inc. ("Marinus" or...
- 2y agoMRNSFaruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on August 5, 2024 in Marinus LawsuitPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Marinus Pharmaceuticals, Inc. ("Marinus" or...
- 2y agoMRNSSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MarinusGlobeNewswireIf you purchased or acquired securities in Marinus stock or options between March 17, 2021 and May 7, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at
- 2y agoMRNSMarinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency DisorderBusiness WireMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products
- 2y agoMRNSMarinus Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before August 5, 2024 to Discuss Your Rights - MRNSPR NewswireThe Gross Law Firm issues the following notice to shareholders of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS). Shareholders who purchased shares of...
- 2y agoMRNSSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MarinusPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Marinus Pharmaceuticals, Inc. ("Marinus" or...
- 2y agoMRNSMarinus Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before August 5, 2024 to Discuss Your Rights - MRNSPR NewswireThe Gross Law Firm issues the following notice to shareholders of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS). Shareholders who purchased shares of...
- 2y agoMRNSMarinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status EpilepticusBusiness WireRAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on the second co-primary
- 2y agoMRNSMarinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex ProgramBusiness WireEnrollment complete in Phase 3 TrustTSC trial with topline data anticipated in the first half of Q4 2024 USPTO grants additional method of use patent for ganaxolone in TSC Marinus Pharmaceuticals, Inc.
- 2y agoMRNSMarinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsBusiness WireZTALMY® (ganaxolone) Q1 2024 net product revenue of $7.5 million representing strong growth of 125% versus Q1 2023 Increased full year 2024 projected U.S. ZTALMY net product revenues to between $33 and $35
- 2y agoMRNSMarinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare ConferenceBusiness WireMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief
- 2y agoMRNSMarinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024Business WireMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for
- 2y agoMRNSMarinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial ResultsBusiness WireTrial did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024 Future development of IV
- 2y agoMRNSMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to two new
- 2y agoMRNSMarinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus' Post Grant ReviewBusiness WireMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to developing and commercializing innovative therapeutics to treat seizure disorders, today affirmed its commitment to defending its patent
- 2y agoDMACMRNSNKTRDiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial ResultsBusiness WireConference Call and Webcast March 20 at 8:00 AM Eastern Time / 7:00 AM Central Time ReMEDy2 Clinical Site Activation Commenced in December 2023 Strengthened Management Team with Lorianne Masuoka, M.D., as Chief
- 2y agoMRNSMarinus Pharmaceuticals, Inc. (MRNS) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoMRNSMarinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsBusiness WirePhase 3 RAISE trial interim analysis enrollment target achieved with Data Monitoring Committee (DMC) review scheduled and topline results expected in first half of Q2 2024 Phase 3 TrustTSC trial approximately 85%
- 2y agoMRNSMarinus Pharmaceuticals to Present at Upcoming Investor ConferencesBusiness WireMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present at and participate
- 2y agoMRNSMarinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024Business WireMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for
- 2y agoMRNSMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to four new
- 2y agoDMACMRNSNKTRDiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical OfficerBusiness WireExecutive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for
- 2y agoMRNSMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to one new
- 2y agoMRNSMarinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business UpdateBusiness WireZTALMY® (ganaxolone) Q4 2023 preliminary net product revenue of between $6.5 and $6.7 million; full year 2023 preliminary net product revenue of between $19.5 and $19.7 million Projected full year 2024 U.S.
- 2y agoMRNSMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to four new
- 2y agoMRNSMarinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD StudyBusiness WireEpilepsia publishes two-year open-label extension Marigold trial data of ZTALMY® (ganaxolone) oral suspension CV in patients with CDKL5 deficiency disorder (CDD) In preliminary results from a Phase 1 multiple
- 2y agoMRNSMarinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx ConferenceBusiness WireMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief
- 3y agoMRNSMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business WireMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to one new
- 3y agoMRNSMarinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial ResultsBusiness WireZTALMY® (ganaxolone) Q3 net product revenue of $5.4 million; 2023 net product revenue guidance increased to between $18.5 and $19 million Over 75% of patients required for the interim analysis are now enrolled
- 3y agoMRNSMarinus Pharmaceuticals Initiates Global Access Program for ZTALMY® (ganaxolone) Oral Suspension CVBusiness WireZTALMY is approved by the U.S. Food and Drug Administration and the European Commission for appropriate patients with CDKL5 deficiency disorder The program enables physicians to request ZTALMY for eligible patients in